Alendronate to Prevent Loss of Bronchoprotection in Asthma

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions
Asthma
Interventions
DRUG

Alendronate

DRUG

Placebo

Trial Locations (10)

27157

Wake Forest University Health Sciences, Winston-Salem

53972

University of Wisconsin, Madison

60611

Northwestern Memorial Hospital, Chicago

60612

University of Illinois at Chicago, Chicago

60637

University of Chicago, Chicago

63110

Washington University, St Louis

80206

National Jewish Health, Denver

85724

University of Arizona College of Medicine, Tucson

94143

University of California - San Francisco, San Francisco

02115

Brigham & Women's Hospital, Boston

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Milton S. Hershey Medical Center

OTHER

NCT02230332 - Alendronate to Prevent Loss of Bronchoprotection in Asthma | Biotech Hunter | Biotech Hunter